Anupam Rasayan Acquires 47.95% Stake in Bliss GVS Pharma, Gains Control
Anupam Rasayan India Limited acquired 47.95% of Bliss GVS Pharma for ₹162.74 crore, gaining control and promoter status. The company, along with a PAC, now holds 50.07% of Bliss GVS Pharma's shares. The acquisition aims to strengthen Anupam Rasayan's presence in the pharmaceutical value chain.
Gaining control of another company and becoming a promoter has a substantial impact on Anupam Rasayan's market position, strategic direction, and potential for future growth and synergies.
The acquisition of a controlling stake in another company and gaining promoter status is a significant positive development, indicating strategic expansion and growth for Anupam Rasayan India Limited.
Anupam Rasayan India Limited has successfully completed the acquisition of 5,09,84,595 equity shares in Bliss GVS Pharma Limited, representing 47.95% of its equity share capital, as of September 28, 2026. This acquisition was made pursuant to a share purchase agreement dated May 23, 2026, and a deed of adherence dated July 17, 2026.
In addition to the shares acquired through the open offer, which saw 1,669 equity shares tendered and credited to Anupam Rasayan on August 24, 2026, the company further acquired 22,50,000 equity shares of Bliss GVS Pharma through an on-market transaction on September 28, 2026. The total cash consideration for the acquisition amounts to ₹162,73,98,675.00, with shares acquired at a price of ₹723.2883 per equity share.
Following these acquisitions, Anupam Rasayan India Limited and Mates Visa Consultancy Private Limited collectively hold 5,32,36,264 equity shares, representing 50.07% of Bliss GVS Pharma's equity share capital. Consequently, Anupam Rasayan and Mates Visa Consultancy have acquired control of Bliss GVS Pharma and have been designated as its promoters, effective September 28, 2026. The board of directors of Bliss GVS Pharma has noted this change in control and promoter designation.
What to do with a filing like this
Anupam Rasayan India Limited filed this with the NSE as a statutory disclosure, categorised under substantial acquisition of shares and takeovers. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Anupam Rasayan India Limited. Read the original for the full detail.